Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Thyroid test combination proves effective
June 2019
SHARING OPTIONS:

PARSIPPANY, N.J.—Interpace Diagnostics Group Inc. opened May with the news that data from its thyroid registry had been published in Diagnostic Cytopathology, detailing results from a two-year, real-world, retrospective study. Looking at more than 300 samples, the data showed that combining Interpace’s ThyGenX thyroid oncogene panel together with ThyraMIR, its micro-RNA classifier, was able to help avoid unnecessary surgeries and target nodules that do require surgical intervention. The study demonstrated that surgical decisions made with the two tests were aligned with risk of malignancy over several years of follow-up. Interpace also conducted a bridge study using ThyGenX and ThyGeNEXT, its mutation panel, that showed 100-percent agreement between the tests, and is now working on a multi-site clinical validation study of ThyGeNEXT in combination with ThyraMIR.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.